Cite this article
89
Downloads
1
Citations
568
Views
Announcements
Open Access
Editorial
New anti-diabetic agents: major advances with unanswered questions
Show Less
1
Heart Institute and ACTION Group, Pitié-Salpétrière, Sorbonne University, 47-83 Boulevard de l’Hôpital, 75013, Paris, France
2
Division of Cardiology, Department of Medical Sciences, University of Turin, “Città della Salute e della Scienza” hospital, 10100, Turin, Italy
3
Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100, Latina, Italy
4
Mediterranea Cardiocentro, 80100, Napoli, Italy
*Correspondence: cardiology.sabouret@gmail.com (Pierre Sabouret)
Rev. Cardiovasc. Med. 2020, 21(4), 489–492;
https://doi.org/10.31083/j.rcm.2020.04.220
Submitted: 19 October 2020 | Revised: 6 December 2020 | Accepted: 8 December 2020 | Published: 30 December 2020
Copyright: © 2020 Sabouret et al. Published by IMR Press.
This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Abstract
No abstract present
Keywords
Diabetes mellitus
SGLT2i
GLP1-RA
heart failure
chronic kidney disease
Figures
Fig. 1.